Renaissance Technologies - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 52 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2015. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q2 2023$739
-11.3%
321,128
+16.8%
0.00%0.0%
Q1 2023$833
+915.9%
274,991
+682.6%
0.00%
Q4 2022$82
-99.9%
35,136
-23.0%
0.00%
Q3 2022$87,000
-97.4%
45,660
-95.5%
0.00%
-100.0%
Q1 2021$3,345,000
+115.1%
1,004,500
+129.4%
0.00%
+100.0%
Q4 2020$1,555,000
+1300.9%
437,963
+615.5%
0.00%
Q2 2020$111,000
-56.8%
61,207
-63.6%
0.00%
Q3 2019$257,000
-30.7%
168,312
-5.5%
0.00%
Q2 2019$371,000
-19.5%
178,200
+265.4%
0.00%
Q3 2018$461,000
-84.9%
48,766
-90.1%
0.00%
-100.0%
Q2 2018$3,048,000
+150.2%
494,152
+102.9%
0.00%
+100.0%
Q1 2018$1,218,000
-40.1%
243,500
-39.5%
0.00%
-50.0%
Q4 2017$2,033,000
+104.1%
402,573
+150.7%
0.00%
+100.0%
Q3 2017$996,000
+31.6%
160,610
-23.6%
0.00%0.0%
Q2 2017$757,000
+86.9%
210,239
+68.8%
0.00%0.0%
Q1 2017$405,000
+1091.2%
124,573
+785.1%
0.00%
Q4 2016$34,000
-91.5%
14,074
-87.9%
0.00%
-100.0%
Q3 2016$399,000
+46.7%
116,100
+48.4%
0.00%0.0%
Q2 2016$272,000
-76.2%
78,215
-71.7%
0.00%
-50.0%
Q1 2016$1,143,000
-27.8%
276,800
-22.2%
0.00%
-33.3%
Q4 2015$1,584,000
+136.1%
356,000
+223.3%
0.00%
+50.0%
Q3 2015$671,000110,1000.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q4 2015
NameSharesValueWeighting ↓
Whitefort Capital Management, LP 11,895,477$24,147,81812.66%
Two Seas Capital LP 8,280,818$16,810,0613.38%
FourWorld Capital Management LLC 1,341,907$2,724,0710.51%
Tejara Capital Ltd 180,077$365,5560.21%
Woodline Partners LP 4,719,903$9,581,4030.11%
Hudson Bay Capital Management LP 8,299,808$16,848,6100.07%
Kepos Capital LP 155,691$3160.06%
Virtus ETF Advisers LLC 40,040$81,2810.05%
Centiva Capital, LP 1,071,705$2,175,5610.05%
Kades & Cheifetz LLC 20,000$40,6000.03%
View complete list of ARBUTUS BIOPHARMA CORP shareholders